SCHEMBL3070982

SCHEMBL3070982

COc1ccccc1C(=O)N1CCC1C(N)=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.54
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
MAPK14 Q16539 1/20 0.50
HTR1A P08908 1/20 0.48
HTR7 P34969 1/20 0.48
LMNA P02545 2/20 0.48
HSD11B1 P28845 1/20 0.48
KMT2A Q03164 1/20 0.48
TSHR P16473 1/20 0.48
ALDH1A1 P00352 1/20 0.48
KDM4E B2RXH2 2/20 0.47
MGLL Q99685 1/20 0.47
CHRM2 P08172 1/20 0.47
CHRM4 P08173 1/20 0.47
CHRM5 P08912 1/20 0.47
CHRM1 P11229 1/20 0.47
CHRM3 P20309 1/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13570607 0.92 HTR1A (0.57) HTTCYP2C9CYP2C19MAPK14HTR1A
SCHEMBL3070988 0.80 HTT (0.52) HTTCYP2C9CYP2C19MAPK14LMNA
SCHEMBL15743803 0.80 HTT (0.56) HTTCYP2C9CYP2C19MAPK14LMNA
SCHEMBL13570451 0.78 MEN1 (0.67) HTTHTR1AHTR7KMT2ATSHR
SCHEMBL3058143 0.77 HCRTR1 (0.49) LMNATSHRALDH1A1
SCHEMBL3063120 0.77 ALDH1A1 (0.49) HTTCYP2C9CYP2C19MAPK14LMNA
SCHEMBL14828685 0.76 HTT (0.56) HTTCYP2C9CYP2C19MAPK14LMNA
SCHEMBL14664115 0.76 HTT (0.56) HTTCYP2C9CYP2C19MAPK14LMNA
SCHEMBL6276557 0.76 HTT (0.58) HTTCYP2C9CYP2C19MAPK14LMNA
SCHEMBL17502621 0.76 KMT2A (0.68) HTTCYP2C9CYP2C19MAPK14LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222600-A1 AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222600-A1 AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R HTT 473/4885CYP2C9 1183/4885CYP2C19 670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.